心脏结构剂量与总生存的关联:III期NSCLC多机构数据库多变量分析及外部验证
本研究基于五个机构1587例III期非小细胞肺癌患者,分析心脏整体、四个心腔、大血管及其组合的剂量学参数与总生存的关联。通过交叉验证筛选参数并建立多变量Cox模型,在独立测试集进行外部验证。结果显示左侧D5%被选为心血管参数(aHR 1.007 Gy-1,95%CI 1.004-1.010,p<0.0001),但模型一致性指数提升很小。作者认为心血管参数与生存的关联虽显著,效应量小,在优先考虑心脏保护时应予考量。
要点
- 低Dx%参数与总生存关联最强,但增量贡献小、效应量小。
- 参数选择确定左侧D5%为心血管参数,aHR 1.007 Gy-1(95%CI 1.004-1.010,p<0.0001)。
- 模型一致性指数提升在训练集为0.0062(95%CI 0.0000-0.0127),测试集为0.0037(95%CI -0.0200-0.0280)。
核心结论
- 心血管参数与生存存在显著关联,但效应量小,在III期NSCLC治疗中优先考虑心脏保护时应予考量。
研究设计与样本
- 多机构回顾性队列分析,纳入五个机构1587例III期NSCLC患者,数据集分为训练集(四个机构)和测试集(一个机构)。
主要发现
- 低Dx%参数与总生存关联最强,但相较于仅含临床和肺剂量学参数,其增量贡献小、效应量小。
- 参数选择确定的心血管参数为左侧D5%,aHR 1.007 Gy-1(95%CI 1.004-1.010 Gy-1,p<0.0001)。
- 模型一致性指数提升在训练集为0.0062(95%CI 0.0000-0.0127),在测试集为0.0037(95%CI -0.0200-0.0280)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Inconsistencies in identifying dose-limiting cardiovascular substructures for treating stage III non-small cell lung cancer (NSCLC) have hindered the implementation of cardiac sparing treatment planning guidelines. This study aims to address these inconsistencies by performing a multivariable survival analysis with overall survival as the endpoint using a large, multinational database, followed by external validation. MATERIALS AND METHODS: Clinical and dosimetric parameters from 1587 stage III NSCLC patients treated at five institutes were analyzed. The whole heart, four cardiac chambers, great vessels and their combinations were considered. The dataset was divided into a training set (four institutes) and a test set (one institute). The optimal parameter set was identified through cross-validation, and the resulting multivariable Cox regression model was externally validated using the test set. Adjusted hazard ratios (aHRs) for all cardiovascular parameters were evaluated. RESULTS: The strongest associations were found for low Dx% parameters. However, their incremental contribution to model performance, compared to clinical and lung dosimetric parameters only, was low, with small effect sizes. Specifically, the cardiovascular parameter identified by parameter selection was Left Side D5% (aHR: 1.007 Gy-1, 95 % CI: 1.004 - 1.010 Gy-1, p < 0.0001), which provided a slight improvement in model concordance index of 0.0062 (95 % CI: 0.0000-0.0127) in the training set and 0.0037 (95 % CI: -0.0200-0.0280) in the test set. CONCLUSIONS: Although significant associations between cardiovascular parameters and survival were found, their small effect sizes should be considered when prioritizing cardiac sparing in stage III NSCLC treatment.
引用
- Garrett Fernandes M, Bussink J, Wijsman R, et al. Association between dose to cardiac structures and overall survival: A multivariable analysis in a large, multi-institutional database of stage III NSCLC patients with external validation. Radiother Oncol. 2025. PMID: 39993599. doi:10.1016/j.radonc.2025.110821
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。